Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis

Jaafar, Mohamed Hasif; Safi, Sher Zaman; Tan, MP; Rampal, Sanjay; Mahadeva, Sanjiv

doi:10.1007/s10620-017-4871-9

Cited by 42 publications

(36 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Especially in patients with organic dyspepsia, symptoms decreased by 28.0%, which was statistically significant, but there was no significant improvement in FD. 134 The mechanism by which rebamipide decreases dyspeptic symptoms seems to be that it improves chronic gastritis. When symptom score was used as the outcome variable, symptoms were improved in FD as well as in organic dyspepsia.…”

Section: Gastroprotective Agents and Othersmentioning

confidence: 99%

Clinical Practice Guidelines for Functional Dyspepsia in Korea

Kwon

Jung

et al. 2020

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Functional dyspepsia (FD) is a chronic upper gastrointestinal (GI) symptom complex that routine diagnostic work-up, such as endoscopy, blood laboratory analysis, or radiological examination, fails to identify a cause. It is highly prevalent in the World population, and its response to the various available therapeutic strategies is only modest because of the heterogenous nature of its pathogenesis. Therefore, FD represents a heavy medical burden for healthcare systems. We constituted a guideline development committee to review the existing guidelines on the management of functional dyspepsia. This committee drafted statements and conducted a systematic review and meta-analysis of various studies, guidelines, and randomized control trials. External review was also conducted by selected experts. These clinical practice guidelines for FD were developed based on evidence recently accumulated with the revised version of FD guidelines released in 2011 by the Korean Society of Neurogastroenterology and Motility. These guidelines apply to adults with chronic symptoms of FD and include the diagnostic role of endoscopy, Helicobacter pylori screening, and systematic review and meta-analyses of the various treatment options for FD (proton pump inhibitors, H. pylori eradication, and tricyclic antidepressants), especially according to the FD subtype. The purpose of these new guidelines is to aid the understanding, diagnosis, and treatment of FD, and the targets of the guidelines are clinicians, healthcare workers at the forefront of patient care, patients, and medical students. The guidelines will continue to be revised and updated periodically. (J Neurogastroenterol Motil 2020;26:29-50)

show abstract

Section: Gastroprotective Agents and Othersmentioning

confidence: 99%

Clinical Practice Guidelines for Functional Dyspepsia in Korea

Kwon

Jung

et al. 2020

J Neurogastroenterol Motil

View full text Add to dashboard Cite

show abstract

“…В настоящий момент доказательная база эффективности гастропротективных препаратов при ФД продолжает активно формироваться. Так, в недавно опубликованном метаанализе оценивалась эффективность гастропротективного препарата ребамипид у пациентов с ФД и органической диспепсией [50]. Данная работа, обобщившая результаты 17 РКИ (2170 пациентов), продемонстрировала, что терапия ребамипидом была ассоциирована с уменьшением симптомов диспепсии в сравнении с плацебо / контрольными препаратами (ОШ 0,77; 95% ДИ 0,64-0,93, р < 0,001) [50].…”

Section: лечениеunclassified

“…Так, в недавно опубликованном метаанализе оценивалась эффективность гастропротективного препарата ребамипид у пациентов с ФД и органической диспепсией [50]. Данная работа, обобщившая результаты 17 РКИ (2170 пациентов), продемонстрировала, что терапия ребамипидом была ассоциирована с уменьшением симптомов диспепсии в сравнении с плацебо / контрольными препаратами (ОШ 0,77; 95% ДИ 0,64-0,93, р < 0,001) [50]. Отдельно стоит упомянуть, что в одном из РКИ было показано, что терапия ребамипидом, помимо купирования симптоматики ФД, оказывает положительное влияние на динамику индикаторов качества жизни пациентов [51].…”

Section: лечениеunclassified

Functional dyspepsia: from pathogenesis to therapeutic aspects

et al. 2019

View full text Add to dashboard Cite

Functional dyspepsia (FD) is one of the most common gastroenterological diseases. The article presents modern views on the pathogenesis of the disease. It is shown that disorders of motor skills (retardation of voiding function, disturbance of relaxation accommodation) and stomach sensitivity (visceral hypersensitivity to stretching) are considered to be one of the main pathophysiological mechanisms of FD. The authors present a modern algorithm of treatment of patients with FD, based on the clinical recommendations of the Rome Consensus IV revision (2016) and the Russian Gastroenterological Association (2017). The strategy of differentiated use of pharmaceuticals for different variants of FD is considered.

show abstract

“…In this issue of Digestive Diseases and Sciences, Jaafar et al [2] demonstrate that rebamipide, a drug used mostly in Asia and Russia intended to enhance foregut mucosal defense mechanisms such as mucus and bicarbonate secretion, improved symptoms in individuals with dyspepsia. The authors performed a rigorous meta-analysis that included 17 studies comparing rebamipide, administered with or without antisecretory agents, to placebo, to a comparator medication, or to no treatment.…”

mentioning

confidence: 99%

“…Rebamipide purportedly activates cyclooxygenase, enhancing prostaglandin release while inhibiting inflammatory cytokines and scavenging free radicals [2]. Prostaglandins are among the key mediators at the epithelial level that protect the gastric mucosa from injury, along with multiple pre-epithelial, epithelial, and microvascular factors [8].…”

mentioning

confidence: 99%